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The new year of 2015 brought with it the release of the update to the Centers for Disease 
Control and Prevention (CDC)'s National Healthcare Safety Network (NHSN) urinary tract 
infection (UTI) definitions. Although the NHSN UTI definitions were last updated in 2009, 
the inclusion of catheter-associated UTIs (CAUTIs) in the Centers for Medicare & Medicaid 
Services' Inpatient Quality Reporting Program in 2012 heightened the challenges to the 
definitions by many professionals involved in infection prevention. Feedback to CDC 
beginning in 2012 highlighted the gap between clinical and surveillance determinations of 
CAUTI1, raised questions about the clinical relevance of some CAUTIs reported to NHSN 
and drew attention to variability in the application of, and adherence to, the UTI surveillance 
criteria and differences in clinical laboratory practices relevant to the criteria. Many 
commenters questioned the validity and fairness of using CAUTI data for public reporting 
and payment purposes and called for definitions which would more accurately measure the 
success of CAUTI prevention activities.
For these reasons, in early 2013, CDC began a systematic process of reviewing the NHSN 
UTI definitions. The main objectives of this work were to: 1) improve the objectivity, 
credibility, and reliability of the UTI definitions, 2) promote best practices for patient safety 
with a metric that is reflective of the success or failure of quality improvement and 
prevention activities, 3) develop a metric that is amenable to full electronic capture to allow 
for increased objectivity and reduced burden of data collection, and 4) help target CAUTI 
prevention.
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As part of the definition review process, CDC created an internal working group and 
identified a 14-member panel of external subject matter experts to assist in reviewing the 
issues related to the UTI surveillance definitions. The external experts included 
representatives from a variety of healthcare facility types, and public health agencies. 
Infection preventionists, microbiologists, infectious disease physicians, hospitalists, hospital 
epidemiologists, senior hospital and corporate administration, and other experts in CAUTI 
prevention all offered their insights and recommendations. CDC also worked with the 
Association of Professionals in Infection Control and Epidemiology (APIC) to conduct a 
survey of urine culturing and urinalysis practices in a convenience sample of laboratories. 
Data from NHSN were analyzed to address specific questions that arose during the 
discussions, and relevant literature was reviewed. Data and proposed definition 
modifications were presented to the Healthcare Infection Control Practices Advisory 
Committee (HICPAC) for discussion and feedback during two public meetings.2 The major 
topics discussed included: 1) whether to include in the definitions, UTIs caused by yeasts; 2) 
whether urine cultures with low concentrations of organisms (i.e., < 100,000 colony forming 
units [CFU]/ml) should be a part of the UTI criteria; 3) whether urinalysis results should be 
a part of the UTI criteria; 4) options to improve the specificity of the UTI criteria, 
particularly in cases where fever is the only sign present; and, 5) whether modifications 
should be made to the UTI criteria for special populations (e.g., spinal cord injury patients).
The inclusion of yeasts such as Candida spp. as pathogens in the UTI definitions was one of 
the most frequently raised concerns by NHSN users. Yeasts are a common cause of CAUTIs 
reported to NHSN, particularly from intensive care units (ICUs); in 2013, yeasts accounted 
for 26.1% of CAUTIs reported (32.1% of CAUTIs from ICUs and 7.7% of CAUTIs from 
non-ICUs). However, in clinical practice, urine cultures positive for yeast, even >100,000 
CFUs/ml, in hospitalized adult patients are typically considered urinary device colonization 
rather than infection,3 and a randomized, controlled trial showed no clinical benefit of 
treatment with fluconazole among asymptomatic or minimally symptomatic patients.4 
Guidelines do not generally recommend therapy for treatment of asymptomatic candiduria. 
NHSN user feedback indicated that the lack of clinical relevance of yeast in urine cultures 
sometimes resulted in administrative overruling and underreporting by some facilities. In 
addition, the survey of clinical laboratories indicated variability in quantifying and reporting 
of yeasts in urine, resulting in facility differences in CAUTI reporting on the basis of 
existing laboratory practices.
Concern among the working group was raised about potential unintended consequences of 
removing yeasts from the definition, such as reducing incentives for facilities to remove 
urinary catheters. However, these theoretical concerns were weighed against the clinical 
concerns and the need for measures that can be applied fairly across most facilities and 
inform prevention efforts. Furthermore, reclassification of fungemia from secondary to 
primary bloodstream infections as a result of removing yeasts from the UTI definitions was 
considered favorable since yeast in the bladder rarely result in ascending urinary tract 
infection and seeding of the bloodstream.5,6 In 2013, 1.0% of CAUTIs with yeast as the sole 
pathogen were reported to have secondary bloodstream infections. The reclassification of 
secondary fungemias as primary may better inform central line-associated bloodstream 
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infection (CLABSI) prevention efforts, acknowledging that the reverse misclassification 
may occur, particularly in immunocompromised patients. Tracking fungemia within the 
CLABSI data reported to NHSN will provide an on-going means of monitoring fungal 
infections with the most impact on patient safety. Therefore, to improve the clinical 
credibility of the UTI surveillance definitions and to reduce the variability in reporting, the 
CDC internal working group opted to remove yeasts from the UTI criteria. For the same 
reasons other rarely-reported non-bacterial pathogens (including non-yeast molds, virus and 
parasites) were also removed from the criteria. These pathogens represented < 0.2% of all 
reported CAUTIs between January 2009 and March 13, 2015.
The inclusion of urine cultures with low colony counts (<100,000 CFU/ml) in the UTI 
definitions was another issue considered by the working group and external experts. In the 
previous definition scheme, these cases were captured by the symptomatic UTI (SUTI) 2 
definition7 and required presence of a positive urinalysis in addition to at least one specified 
sign or symptom. Although a definitive CFU cut-off representing true UTI in catheterized 
patients has not been defined, such cut offs have been long recognized for bacteruria in non-
catheterized women and lower concentrations of organisms in catheterized patients have 
been considered more likely to represent urinary colonization or contamination than 
infection.8 Debate arose because some data point to the significance of urine cultures with 
lower colony counts, particularly one publication demonstrating that lower colony counts of 
growth in the urine quickly rise to > 100,000 CFU/ml and therefore may be clinically 
significant.9 In addition, analysis of January 2009-May 2013 NHSN data demonstrated that 
the incidence of reported secondary bloodstream infection was similar for CAUTIs meeting 
the SUTI 17 (6.1%) and SUTI 2 (5.2%) criteria. However, potential problems in the 
reporting of CAUTIs with lower colony counts were identified. Analysis of 2013 NHSN 
data showed that < 10% of the CAUTIs reported to NHSN met the SUTI 2 definition and 
that only 43% of hospitals reporting CAUTIs used the SUTI 2 definition at all. Supporting 
the NHSN data, the clinical laboratory survey found that only 29% of the approximately 345 
responding laboratories used a threshold as low as ≥ 1,000 CFU/ml (the SUTI 2 threshold) 
to trigger minimal identification of organisms in urine specimens collected from indwelling 
catheters, which is necessary for NHSN data entry. The apparent variability in the use of low 
colony count criteria for reporting suggests that the SUTI 2 data are not representative of 
what may actually be occurring in hospitals, and that facilities whose laboratories identify 
organisms from low colony counts may be penalized for reporting more CAUTIs than those 
whose laboratories don't. Therefore, the CDC internal working group decided to limit the 
threshold for the UTI surveillance definitions to ≥ 100,000 CFU/ml.
The working group also considered the use of the urinalysis as an element of the UTI 
definitions. In an effort to improve the specificity of the SUTI 2 criteria, the previous 
definitions required a positive urinalysis, defined as the presence of pyuria, leukocyte 
esterase, nitrite, or positive gram stain, when the urine culture colony count was < 100,000 
CFU/ml. However, pyuria, particularly in the setting of a urinary catheter, is a non-specific 
finding and cannot be used to distinguish infection from colonization.10 On the other hand, 
because the absence of pyuria suggests a diagnosis other than UTI,10 consideration was 
given to the use of a negative urinalysis to allow for exclusion of reporting of bacteriuria as 
a UTI in immunocompetent patients. Review of the literature and discussions with 
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laboratory experts indicated that no standardized laboratory criteria for a positive or negative 
urinalysis have been defined, precluding the use of this measure for the surveillance 
definition. For this reason, the working group decided on the removal of urinalysis results as 
part of the NHSN UTI criteria.
Finally, the use of fever and other signs and symptoms used to meet the UTI definition were 
reviewed. The first issue focused on the requirement to report a CAUTI with fever as the 
sole symptom even if another possible source of fever is identified. For the purposes of 
objectivity and equity, NHSN rules serve to minimize the use of clinical judgment in the 
reporting of healthcare-associated infections. Between January 1, 2009 and January 31, 
2013, the majority of CAUTIs reported to NHSN used fever as the sole clinical criterion to 
meet the definition (79.7%). This is likely related to the absence of UTI-specific signs or 
symptoms in many hospitalized patients, a lack of assessment and/or documentation of such 
signs or symptoms, and methodologies reportedly used by some hospital surveillance 
programs (surveillance only for fever rather than full chart review).
The working group and external experts considered other alternatives to the current NHSN 
protocols, such as excluding reporting of a CAUTI if another NHSN-defined source of fever 
is identified. However, this strategy would require the identification of a hierarchy of 
infections deemed more likely to cause fever than UTI, a process that would be fraught with 
subjectivity and would create additional burden on infection preventionists who would be 
required to consider and rule out multiple alternative types of infection. A future automated 
hierarchical algorithm may be possible when data are fully captured electronically, but for 
now the decision was made to continue the current rules. It is likely that the changes to the 
definitions (i.e., removal of yeast and lower colony counts) will improve the specificity of 
the UTI criteria and reduce the potential impact of fever due to other sources. The working 
group members were also in agreement that no additional signs or symptoms would add 
value to the UTI definitions because of lack of objectivity, specificity, and feasibility for 
surveillance, particularly for future electronic capture. Signs and symptoms in special 
populations such as spinal cord injury patients11 were discussed in detail but were deemed 
too non-specific or difficult to capture for the purposes of surveillance.
Our UTI definition review was multidisciplinary and extensive, but several operational 
limitations affected the scope and process of the review. Limited available data led us to rely 
on the best available scientific evidence and expert consensus to reach decisions. An 
analysis of clinical correlation of the revised definitions was not performed and would be 
limited by the lack of a gold standard clinical definition of CAUTI. In addition, because 
there are no clinical biomarkers for UTI or standardized criteria for existing measures such 
as the urinalysis, we could not incorporate additional, objective laboratory criteria to 
improve the specificity of the definitions. With advances in diagnostic technology and 
further research to determine the association of objective laboratory criteria with clinical 
findings, we hope that more objective criteria can be used in the future, both for clinical and 
surveillance purposes. Finally, we attempted to better understand current clinical laboratory 
practices for UTI diagnosis with a survey of clinical laboratories conducted by APIC. While 
the survey was useful in the variability of practices it revealed, it cannot be considered 
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representative of all clinical laboratories as only approximately 340 out of > 14,000 invited 
facilities responded.
In summary, CDC has responded to user and stakeholder feedback by completing an 
extensive review and revision of the NHSN UTI definitions. The objective was to modify 
the definitions to create a meaningful comparative metric with maximal credibility, 
objectivity, equitability, and amenability to future transition to electronic surveillance, and 
to guide CAUTI prevention. Improving the credibility of the definition will hopefully 
narrow the gap between clinical and surveillance definitions and focus more attention on 
implementing CAUTI prevention practices and less on the definitions. The need to have 
surveillance definitions that use objective criteria that all facilities can meet in a similar 
manner to improve comparability of reported data highlights the gap between surveillance 
and clinical definitions; UTIs captured by surveillance serve as a proxy indicator and may 
not be inclusive of all clinical UTIs. Importantly, the definition review has highlighted the 
need for collaborations between public health and professional societies to develop clinical 
laboratory standards for urine culturing and urinalysis.
Given that CAUTIs identified by the revised criteria will be a subset of the previous 
CAUTIs captured, it will be possible for facilities to estimate previous CAUTI rates and 
SIRs to allow for trend analysis over time; however, several other general changes were 
made to the NHSN HAI definitions in 2015, the impacts of which are unknown. These 
include 1) the institution of a 7-day infection window period, 2) the institution of a 14-day 
repeat infection window period, and 3) changing the definition of the date of event from the 
date of the last element of the infection criteria to the date that the first infection element 
occurred during the infection window. These modifications to HAI surveillance definitions 
will each affect the reporting of CAUTIs by changing the time period during which all 
elements of infection must be present to meet criteria, how new infections are discriminated 
from previous infections, or how infections are determined to be present on admission vs. 
healthcare-associated. These changes will also improve objectivity and more easily enable 
transition to electronic surveillance. In 2016, CAUTI SIRs will be calculated using a new 
baseline of 2015 data, and CAUTI SIRs will continue to be monitored to determine 
improvement and success of CAUTI prevention activities. It is hoped that the revised metric 
will more accurately reflect the impact of such prevention activities.
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